Skip to content Skip to footer
Subscribe Now
Medical Device Top 20 2024
TOP 20

Top 20 Medical Device Companies of 2024 

Shots:   Bringing innovation and technology to healthcare, the MedTech sector is growing rapidly and transforming the ways diagnosis and treatment are received  With a global market size of $503.2B in 2023, the MedTech sector anticipates reaching $776.4B by 2033 with a CAGR of 4.4 percent. With a staggering revenue of $32.31B, Medtronic ranks first in…
May 9, 2024

Read more

VIEWPOINTS_Meri Beckwith _2024
VIEWPOINTS

Infusing AI in Clinical Trials: Meri Beckwith from Lindus Health in Conversation with PharmaShots

Shots:  Meri Beckwith, Co-Founder of Lindus Health engages in a striking conversation with PharmaShots  Meri talks about bridging the gaps of clinical trials in CNS/Neurology by leveraging LLMs that are trained on nearly a million clinical trial protocols and simple machine learning models to monitor real-time clinical trial data  Meri highlights the importance of multidisciplinary…
May 8, 2024

Read more

VIEWPOINTS_Salomé Juethner_2024
VIEWPOINTS

Takeda at AAAAI 2024: Salomé Juethner highlights P-IV Results from ENABLE and EMPOWER Studies

Shots:  At the American Academy of Allergy, Asthma, & Immunology (AAAAI), Takeda presented 9 abstracts focusing on health equity and real-world data from P-IV (ENABLE) & (EMPOWER) studies evaluating HAE patients  Salomé Juethner, Senior Medical Director-Head of Rare Genetics at Takeda, in a stimulating conversation with PharmaShots, talks about shares insights from the real-world P-IV…
May 6, 2024

Read more

Insights+ Key Biosimilars Events of April 2024
INSIGHTS+

Insights+ Key Biosimilars Events of April 2024

Shots:    Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency     Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients     During April, Samsung Bioepis and Sandoz received the EC’s Marketing Authorization approval for Pyzchiva.…
May 2, 2024

Read more

RNAi Therapeutic Top 20 2024
TOP 20

Top 20 RNAi Therapeutic Companies of 2024

Shots:  RNAi therapeutics are innovative medications that enable rapid identification of specific inhibitors of disease targets across a wide range of molecule classes. Several biopharma companies are investing in RNAi therapeutics extravagantly to maintain a healthy foothold in innovative medicines  In 2023, the global RNAi drug delivery market size was valued at $84.1B and is…
April 25, 2024

Read more

VIEWPOINTS_Mo Jain_2024
VIEWPOINTS

Expanding Services: Mo Jain Sheds Light on Sapient’s Recently Launched Discovery Proteomics Services

Shots:  Following the roll-out of high throughput discovery proteomics services, Mo Jain, Founder and CEO of Sapient engages in a stimulating conversation with PharmaShots  Unlike conventional mass spectrometry-based proteomics methodologies in the market, Sapient’s Discovery Proteomics Services leverage the nanoparticle enrichment technology to measure more proteins and PTMs within the plasma proteome  While highlighting Sapient’s…
April 16, 2024

Read more

Biopharm Top 20 2023
TOP 20

Top 20 Biopharma Companies of 2024

Shots: Driven by innovations and propelled by the pursuit of delivering the best-in-class therapies, 2023 remained a good year for the Biopharma Industry, despite a slight revenue decline, partly due to the conclusion of the COVID-19 pandemic With a CAGR of 7.8 %, the global biopharma industry is anticipated to register a market size of…
April 11, 2024

Read more

Load more